Gilead HIV Cure Mentored Scientist Awards

Note: The Gilead HIV Cure Mentored Scientist award is not currently being offered in the Fall 2021 RAP cycle, but will be offered in Spring 2022.

The purpose of the Gilead HIV Cure Mentored Scientist Award at the amfAR Institute for HIV Cure Research is to mentor and train early stage investigators participating in HIV cure research. The award is open to investigators at a senior stage of clinical or postdoctoral training, and to new faculty at UCSF and affiliated partner institutes. Cure research projects can be in clinical or basic laboratory science and must contribute to the goals of the amfAR Institute for HIV Cure Research. Applicants for this award must indicate a faculty research mentor(s) who will commit to guiding the applicant throughout the duration of the proposed project. Funded through the ARI, the application is processed through the UCSF Resource Allocation Program (RAP).

The award amount for this program is $45,000 in direct costs for one year.

For more information and application deadlines (1-2 times a year), please see the RAP portal.

Spring 2020 Awardee

Koh Fujinaga, PhD

Improving efficacies of latency reversing agents by increasing CycT1 proteins in latently infected cells

Fall 2019 Awardees

Amelia Deitchman, PharmD, PhD

Defining sirolimus dosing targets for HIV cure

Zain Dossani, PhD

Deciphering the regulation of CD8+ T cell hyporesponsiveness in HIV infection by interrogating chromatin accessibility at the single-cell level

Spring 2019 Awardee

Michael Peluso, MD

A comprehensive immunologic analysis of HIV ‘extraordinary’ controllers as a model for durable HIV suppression

Spring 2018 Awardees

Rachel Rutishauser, MD, PhD

Exploring the role of TCF-7 in the regulation of HIV-specific CD8+ T Cell

Daniela Boehm, PhD

Targeting SMYD5 Mediated Tat Methylation to Silence Latent HIV-1”

Spring 2017 Awardees

Leonard Chavez, PhD

Replenishment of the HIV reservoir following reactivation of latent HIV

Andrea Gramatica, PhD

Identifying potent, non-toxic latency reversing agents that function through the mTOR pathway